HGH 191AA: Dosing Protocols

Research Dosing Disclaimer#

The dosing information below is derived from research studies and is provided for educational purposes only. HGH 191AA is not approved for human use, and no official dosing guidelines exist.

Dose-Response Data#

Nonhuman primates

• Single‑dose tolerability: Cynomolgus or rhesus monkeys given a single 6.25 mg/kg SC dose had no acute adverse effects.
• Multi‑week daily dosing: Rhesus monkeys received IM somatropin daily for 5 weeks at 0.125, 0.375, and 1.25 mg/kg/day (up to ~20× anticipated human dose) without treatment‑related abnormalities and without anti‑hGH antibody development (standardUnknownyearbiosynthetichumangrowth pages 37-40, standardUnknownyearbiosynthetichumangrowtha pages 37-40).
• PK/PD and IGF‑1 induction: In juvenile rhesus monkeys, multiple delivery regimens were compared. Daily SC injections of 0.86 mg/day for 28 days, a single large SC dose (~25.9 mg), ProLease microspheres (~24 mg total), and an implanted osmotic pump (~24.4 mg total) were tested. Modeling yielded Smax ≈ 2.2 and SC50 ≈ 6.5 ng/mL for IGF‑1 induction; zero‑order/continuous input (pump or ProLease) produced greater and more sustained IGF‑1 responses than single high‑dose or pulsatile daily dosing, despite similar total dose exposures. Although daily dose in this study was reported as mg/day rather than mg/kg, body‑weight normalization was explicit in other primate tolerability studies above (standardUnknownyearbiosynthetichumangrowth pages 37-40, standardUnknownyearbiosynthetichumangrowtha pages 37-40).
• PK comparator in cynomolgus: In cynomolgus monkeys, an hGH comparator arm at 0.1 mg/kg SC showed a subcutaneous half‑life of ~1.7 h; these data benchmark rapid clearance relative to long‑acting GH constructs.

Safety margins and cross‑species tolerability

• Thirty‑day daily dosing at 0.125–3.125 mg/kg/day IV/SC across species showed no toxicologically significant findings, and acute single‑dose ranges up to 12.5 mg/kg (rodents) and up to 3.125 mg/kg (dogs, IV) were well tolerated; primates tolerated 6.25 mg/kg SC once without acute effects.

Key dose‑response insights

• Growth and bone endpoints in rats increase at very high repeated doses (400 mg/kg SC BID), supporting anabolic effects but exceeding clinical exposure ranges; lower multi‑week daily doses up to 3.125 mg/kg/day across species show tolerability without overt toxicity signals.
• In primates, the magnitude and durability of IGF‑1 elevation depend strongly on delivery profile: continuous exposure yields greater IGF‑1 induction than equal or higher bolus doses, indicating exposure‑response is driven by time above an effective concentration (SC50 ~6.5 ng/mL) rather than peak alone.

A comparative summary of doses, schedules, and outcomes is provided below.

Administration Routes#

We compared pharmacokinetics of recombinant human growth hormone (somatropin, 191-aa) across subcutaneous (SC), intramuscular (IM), oral, and transdermal/topical routes.

Subcutaneous (clinically established)

• Absolute bioavailability: Approximately 63–80% depending on product and study. Janssen et al. reported mean 63% (95% CI 55–71%) in adults with GH deficiency; a compiled table reports product-specific values for SC somatropin near 70–80% (e.g., Humatrope ~75%, Genotropin ~80%).
• Tmax and absorption: Median Tmax about 4–6 hours after SC injection in adults (255–345 min across doses), reflecting relatively slow absorption from subcutaneous tissue.
• Half-life: Apparent terminal half-life after SC dosing is typically several hours across marketed products (about 2–5 h compiled across formulations), longer than the ~20–30 min systemic half-life observed after IV bolus; values vary by product and assay.
• Variability: Considerable interindividual variability in exposure; Cmax coefficients of variation around 20–30% are reported in compiled tables.

Intramuscular (clinically used but less common than SC)

• Absolute bioavailability: Reported ~63% for Humatrope IM in a compiled dataset, broadly similar to SC exposure, with small differences in absorption kinetics.
• Tmax/half-life: Direct quantitative Tmax values for IM were not provided in the excerpts; clinical experience and reviews suggest kinetics similar to SC with potential for somewhat faster absorption depending on site perfusion; terminal half-life remains driven by distribution/clearance and formulation, on the order of hours and similar to SC.

Oral (not clinically available for somatropin)

• Absolute bioavailability: No approved oral somatropin; modern reviews emphasize that even with permeation enhancers, typical clinical oral bioavailability for peptides is around 1% (exemplified by oral semaglutide and octreotide). There are no quantitative data demonstrating clinically meaningful systemic bioavailability for oral somatropin in the provided sources.
• Mechanistic barriers: Gastric and intestinal proteolysis and very low trans-epithelial permeability for a 22 kDa hydrophilic protein limit systemic exposure; enhancer effects are peptide- and context-dependent and generally modest at clinically acceptable doses.

Transdermal/topical (not established clinically for systemic GH; animal data)

• Microneedles: In hairless guinea pigs, a coated microneedle patch (ZP-hGH) produced rapid absorption with Tmax ~30 min, an apparent plasma half-life of ~70 min, and absolute bioavailability around 25–27%, described as similar to SC comparator in that model. Elimination appeared faster post-patch than SC (Kel ~0.5 h−1 vs 0.15 h−1).
• RF microchanneling (ViaDerm) and self-dissolving micropiles (animal): Relative bioavailability versus SC was ~75% in rats and ~32% in guinea pigs for RF microchannel delivery; self-dissolving micropiles in rats yielded an estimated absolute bioavailability of ~87.5% with reported Cmax 132.8 ± 11.8 ng/mL and AUC0–8 432.9 ± 25.3 ng·h/mL.
• Mechanistic context: Passive transdermal delivery of somatropin is negligible due to the stratum corneum barrier; physical disruption (microneedles, RF microchannels) or dissolving microstructures are required for systemic uptake. Human systemic PK after transdermal GH is not established in these excerpts.

Route-comparison summary and implications

• SC vs IM: Both achieve substantial systemic exposure with broadly similar bioavailability; SC is favored clinically for convenience and consistent absorption. SC produces a delayed Tmax (~4–6 h) and an apparent half-life in the 2–5 h range across products, with moderate variability.
• Oral: Systemic delivery of intact somatropin is currently impractical with clinical enhancers; expected oral BA would be near or below ~1% based on the broader peptide literature, far below SC/IM, with major enzymatic and permeability barriers.
• Transdermal/topical: In animals, physically assisted systems can yield a wide BA range (≈25–88%) and faster absorption (e.g., microneedles Tmax ~0.5 h), but translation to humans is not demonstrated here; microneedle PK showed shorter apparent half-life than SC in the animal model.

Mechanistic drivers of route-specific PK

• SC/IM: Absorption-rate limited input from depot tissues, modulated by local blood flow, lymphatic uptake, and formulation; apparent half-life after SC can appear longer than IV due to flip-flop kinetics, while true systemic half-life of GH after IV is ~20–30 min.
• Oral: Proteolysis in the GI lumen and enterocytes plus poor paracellular/transcellular permeability; permeation enhancers (e.g., SNAC, C8) yield limited, peptide-specific gains at clinically acceptable doses.
• Transdermal: Stratum corneum prevents passive diffusion; physical breach (microneedles, RF ablation) enables rapid uptake with device- and species-dependent bioavailability.

Overall, for systemic GH replacement with somatropin 191-aa, SC remains the standard with well-characterized bioavailability and PK; IM is comparable. Oral delivery of somatropin is not clinically viable at present. Transdermal systems show promise in animals but lack established human systemic PK in the cited excerpts.

Human-Equivalent Dosing#

Summary. Human‑equivalent dose (HED) can be estimated by several approaches: body‑surface‑area (BSA/Km) conversions from animal NOAELs for conservative first‑in‑human (FIH) safety starts; body‑weight power‑law (allometric) conversions; pharmacokinetic (PK) allometry of parameters such as clearance (CL ∝ W^0.75) and volume (V ∝ W^1) to project human exposure and back‑calculate dose; and model‑informed strategies (MABEL, PK/PD, TMDD). For somatropin specifically, literature indicates subcutaneous (SC) bioavailability around 50% in humans and largely linear PK over relevant dose ranges in pediatric/adult use and in preclinical models, so HED projections must correct for route and use PK scaling rather than BSA alone when selecting pharmacologically active doses (versus safety starts).

Equations commonly used for animal→human dose translation.

• BSA/Km (dose‑by‑factor) for MRSD: HED (mg/kg) = Animal dose (mg/kg) × (Km_animal / Km_human). Equivalently, using a weight exponent: HED = Animal dose × (W_animal/W_human)^(1−b), with b ≈ 0.67 (so 1−b ≈ 0.33) for conventional drugs; some contexts use b ≈ 0.75 (so 1−b ≈ 0.25). These are typically applied to scale an animal NOAEL to an HED, then divide by a safety factor (often ≥10) to set a conservative MRSD.
• Weight‑based power law (direct dose scaling): HED = Animal dose × (W_animal/W_human)^(1−b), with b chosen from empirical precedent (≈0.67–0.75). This is a coarse alternative when only body weight is available and no PK data exist.
• PK‑parameter allometry: predict human CL and V using CL_h = a·W_h^b (b typically near 0.75 for proteins/biologics) and V_h ≈ a_V·W_h^1; then choose dose to achieve a target exposure (Dose ≈ AUC_target × CL_h, adjusting for F and regimen). This uses multi‑species PK and is preferred when aiming for pharmacologic activity rather than merely a safe start.

When BSA/Km is appropriate and its limits.

• Role: The FDA/EMA safety‑led “dose‑by‑factor” workflow uses animal NOAEL → HED (via BSA/Km or weight exponent) → apply safety factor to derive MRSD for healthy volunteers; PAD/MABEL can supersede MRSD for biologics when pharmacology is potent.
• Limits: Reviews caution BSA‑only conversions are not intended to estimate therapeutic doses, can be inaccurate for biologics, and should not replace mechanistic PK/PD modeling; HED is a conservative safety construct, not a predictor of PAD.

Allometric exponents and corrections used for biologics.

• Clearance and intercompartmental flows: CL typically scales with W^0.75 (reported ranges ~0.65–0.85 in macromolecule datasets); Q often near 0.75.
• Volume: V generally scales ~W^1 (linear with body size).
• Practicalities: Simple allometry requires multi‑species data and may need corrections (e.g., brain‑weight/MLP “rule of exponents”) when slopes deviate; TMDD and species differences in target expression/turnover can break simple scaling.

Somatropin (HGH 191AA) specifics to incorporate in scaling.

• Route correction for SC dosing: Human SC bioavailability for hGH is reported at approximately 50%, with evidence of local degradation at the injection site; SC absorption is affected by lymphatic transport and tissue physiology, which differ by species. Therefore, projected human doses based on animal data should correct for F_SC and absorption kinetics when translating from IV or across species.
• PK linearity in relevant ranges: Pediatric/adult somatropin formulations generally show dose‑proportional Cmax and AUC across studied ranges, and body‑size covariates have modest effects; preclinical monkey studies modeled SC absorption as first‑order (or formulation‑dependent zero‑order release) and assumed linear, stationary PK when linking to IGF‑I. These findings support use of CL/V allometry with linear PK over the studied ranges for pragmatic translation.

Practical workflow for translating animal somatropin doses to an HED.

• Safety‑led FIH (MRSD): Identify animal NOAEL in the most sensitive species → convert to HED via BSA/Km or weight‑exponent formula → divide by an appropriate safety factor (often ≥10) to obtain MRSD; consider MABEL if pharmacology is highly potent or safety margins are uncertain.
• Pharmacology‑led projection (estimating PAD): Fit multi‑species PK to obtain CL and V; scale to human (CL ∝ W^0.75, V ∝ W^1) and simulate human exposure; set dose to achieve target exposure (e.g., IGF‑I response linked to somatropin concentrations) while correcting for human SC bioavailability and absorption profile. This approach better reflects somatropin’s linear PK and route‑specific F, and avoids BSA‑only misestimation.

Key takeaways.

• Methods used in the literature include BSA/Km HED from NOAEL, weight‑based power‑law scaling, PK allometry of CL and V, MABEL, and PK/PD (including TMDD) modeling.
• For somatropin, account for human SC F (~50%) and generally linear PK across typical dose ranges; prefer PK parameter allometry (CL ~ W^0.75; V ~ W^1) and PK/PD modeling to estimate pharmacologically active HEDs, using BSA/Km mainly for conservative safety starts (MRSD).

Evidence Gaps#

• No human dose-finding studies have been completed
• Allometric scaling from animal models has inherent limitations
• Route-specific bioavailability data in humans is absent
• Optimal treatment duration has not been established

Related Reading#

• HGH 191AA overview and research guide
• HGH 191AA side effects profile
• HGH 191AA research evidence